Download PDF
Thromb Haemost 2022; 122(12): 1969-1979
DOI: 10.1055/s-0042-1757200
Review Article

Obesity and the Risk of Venous Thromboembolism after Major Lower Limb Orthopaedic Surgery: A Literature Review

Usha Gurunathan 
1   Faculty of Medicine, The University of Queensland, Brisbane, Australia
2   Department of Anaesthesia and Perfusion Services, The Prince Charles Hospital, Brisbane, Australia
,
Michael Barras
3   School of Pharmacy, The University of Queensland, Brisbane, Australia
4   Pharmacy Department, Princess Alexandra Hospital, Brisbane, Australia
,
Catherine McDougall
1   Faculty of Medicine, The University of Queensland, Brisbane, Australia
5   Department of Orthopaedics, The Prince Charles Hospital, Brisbane, Australia
,
Harshal Nandurkar
6   Department of Haematology, Alfred Health and Australian Centre for Blood Diseases, Monash University, Melbourne, Australia
,
Victoria Eley
1   Faculty of Medicine, The University of Queensland, Brisbane, Australia
7   Department of Anaesthesia and Perioperative Medicine, Royal Brisbane and Women's Hospital, Brisbane, Australia
› Author Affiliations Funding None declared.
› Further Information
    Permissions and Reprints


Abstract

The risk of venous thromboembolism following total joint arthroplasty is significantly greater than those of other types of elective orthopaedic procedures. This risk is increased in obesity due to the associated prothrombotic physiological and hematological changes that predispose to embolic events. The prevalence of obesity is increasing in the aging population, which contributes to a further increase in the risk of postoperative thrombosis in the older patients. There is a lack of clear evidence regarding dosing information for thromboprophylaxis medications in patients with obesity. As a result, the currently available thromboprophylaxis guidelines do not provide specific recommendations for this group. Suboptimal dosing regimens for these medications can place these patients at a risk of bleeding or clotting complications postsurgery. Hence any increase in dosage may require intensive surveillance for the residual anticoagulant effects and careful balancing of risks and benefits on an individual basis. Our review discusses the basis for increased thrombotic risk in obesity, the evidence supporting dosage recommendations, and the implications of the current guidelines for pharmacological thromboprophylaxis in patients with obesity undergoing lower limb arthroplasty.

Keywords

antithrombotic - arthroplasty - obesity - thromboprophylaxis - venous thromboembolism


Publication History

Received: 07 May 2022

Accepted: 02 August 2022

Article published online:
16 November 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 World health organization. Obesity and overweight. Accessed June 5, 2021 at: https://www.Who.Int/news-room/fact-sheets/detail/obesity-and-overweight
    PubMedGoogle Scholar
  • 2 Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in obesity among adults in the united states, 2005 to 2014. JAMA 2016; 315 (21) 2284-2291
    CrossrefPubMedGoogle Scholar
  • 3 Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR). Hip, Knee & Shoulder Arthroplasty Annual Report 2020. Accessed June 28, 2021 at: https://aoanjrr.Sahmri.Com/annual-reports-2020
    PubMedGoogle Scholar
  • 4 Manning L, Davis JS, Robinson O. et al. High prevalence of older Australians with one or more joint replacements: estimating the population at risk for late complications of arthroplasty. ANZ J Surg 2020; 90 (05) 846-850
    CrossrefPubMedGoogle Scholar
  • 5 ANZHFR.. Australian & New Zealand Hip Fracture Registry Annual Report 2022. Accessed September 15, 2022 at: https://anzhfr.org/wp-content/uploads/sites/1164/2022/08/ANZHFR-2022-Annual-Report-Full-e-Report-v2.pdf
    PubMedGoogle Scholar
  • 6 Harris IA, Cuthbert A, de Steiger R, Lewis P, Graves SE. Practice variation in total hip arthroplasty versus hemiarthroplasty for treatment of fractured neck of femur in Australia. Bone Joint J 2019; 101-B (01) 92-95
    CrossrefPubMedGoogle Scholar
  • 7 Hip I-V, Knee D. The ICM-VTE Hip & Knee Delegates. Recommendations from the ICM-VTE: hip & knee. J Bone Joint Surg Am 2022; 104 (Suppl 1): 180-231
    CrossrefPubMedGoogle Scholar
  • 8 Gregson J, Kaptoge S, Bolton T. et al; Emerging Risk Factors Collaboration. Cardiovascular risk factors associated with venous thromboembolism. JAMA Cardiol 2019; 4 (02) 163-173
    CrossrefPubMedGoogle Scholar
  • 9 Hoerlyck C, Ong T, Gregersen M. et al. Do anticoagulants affect outcomes of hip fracture surgery? A cross-sectional analysis. Arch Orthop Trauma Surg 2020; 140 (02) 171-176
    CrossrefPubMedGoogle Scholar
  • 10 Quintero JI, Cárdenas LL, Navas M, Bautista MP, Bonilla GA, Llinás AM. Clinical Care Program in Joint Replacement Surgery. Primary joint arthroplasty surgery: is the risk of major bleeding higher in elderly patients? A retrospective cohort study. J Arthroplasty 2016; 31 (10) 2264-2268
    CrossrefPubMedGoogle Scholar
  • 11 Poultsides LA, Gonzalez Della Valle A, Memtsoudis SG. et al. Meta-analysis of cause of death following total joint replacement using different thromboprophylaxis regimens. J Bone Joint Surg Br 2012; 94 (01) 113-121
    CrossrefPubMedGoogle Scholar
  • 12 Warren JA, Sundaram K, Anis HK, Kamath AF, Higuera CA, Piuzzi NS. Have venous thromboembolism rates decreased in total hip and knee arthroplasty?. J Arthroplasty 2020; 35 (01) 259-264
    CrossrefPubMedGoogle Scholar
  • 13 Barrett MC, Whitehouse MR, Blom AW, Kunutsor SK. Host-related factors for venous thromboembolism following total joint replacement: a meta-analysis of 89 observational studies involving over 14 million hip and knee replacements. J Orthop Sci 2020; 25 (02) 267-275
    CrossrefPubMedGoogle Scholar
  • 14 Bjørnarå BT, Gudmundsen TE, Dahl OE. Frequency and timing of clinical venous thromboembolism after major joint surgery. J Bone Joint Surg Br 2006; 88 (03) 386-391
    CrossrefPubMedGoogle Scholar
  • 15 Ruppert A, Steinle T, Lees M. Economic burden of venous thromboembolism: a systematic review. J Med Econ 2011; 14 (01) 65-74
    CrossrefPubMedGoogle Scholar
  • 16 Sista AK, Klok FA. Late outcomes of pulmonary embolism: the post-PE syndrome. Thromb Res 2018; 164: 157-162
    CrossrefPubMedGoogle Scholar
  • 17 Mula V, Parikh S, Suresh S, Bottle A, Loeffler M, Alam M. Venous thromboembolism rates after hip and knee arthroplasty and hip fractures. BMC Musculoskelet Disord 2020; 21 (01) 95
    CrossrefPubMedGoogle Scholar
  • 18 Pedersen AB, Ehrenstein V, Szépligeti SK, Sørensen HT. Excess risk of venous thromboembolism in hip fracture patients and the prognostic impact of comorbidity. Osteoporos Int 2017; 28 (12) 3421-3430
    CrossrefPubMedGoogle Scholar
  • 19 Matar WY, Jafari SM, Restrepo C, Austin M, Purtill JJ, Parvizi J. Preventing infection in total joint arthroplasty. J Bone Joint Surg Am 2010; 92 (Suppl 2): 36-46
    CrossrefPubMedGoogle Scholar
  • 20 Purdy JC, Shatzel JJ. The hematologic consequences of obesity. Eur J Haematol 2021; 106 (03) 306-319
    CrossrefPubMedGoogle Scholar
  • 21 Rosito GA, D'Agostino RB, Massaro J. et al. Association between obesity and a prothrombotic state: the Framingham Offspring Study. Thromb Haemost 2004; 91 (04) 683-689
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Norgard NB. Obesity and altered aspirin pharmacology. Clin Pharmacokinet 2018; 57 (06) 663-672
    CrossrefPubMedGoogle Scholar
  • 23 Engbers MJ, van Hylckama Vlieg A, Rosendaal FR. Venous thrombosis in the elderly: incidence, risk factors and risk groups. J Thromb Haemost 2010; 8 (10) 2105-2112
    CrossrefPubMedGoogle Scholar
  • 24 Schlaudecker J, Becker R. Inflammatory response and thrombosis in older individuals. Semin Thromb Hemost 2014; 40 (06) 669-674
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Wilkerson WR, Sane DC. Aging and thrombosis. Semin Thromb Hemost 2002; 28 (06) 555-568
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Buerba RA, Fu MC, Gruskay JA, Long III WD, Grauer JN. Obese class III patients at significantly greater risk of multiple complications after lumbar surgery: an analysis of 10,387 patients in the ACS NSQIP database. Spine J 2014; 14 (09) 2008-2018
    CrossrefPubMedGoogle Scholar
  • 27 White RH, Henderson MC. Risk factors for venous thromboembolism after total hip and knee replacement surgery. Curr Opin Pulm Med 2002; 8 (05) 365-371
    CrossrefPubMedGoogle Scholar
  • 28 White RH, Gettner S, Newman JM, Trauner KB, Romano PS. Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. N Engl J Med 2000; 343 (24) 1758-1764
    CrossrefPubMedGoogle Scholar
  • 29 Sloan M, Sheth N, Lee GC. Is obesity associated with increased risk of deep vein thrombosis or pulmonary embolism after hip and knee arthroplasty? A large database study. Clin Orthop Relat Res 2019; 477 (03) 523-532
    CrossrefPubMedGoogle Scholar
  • 30 Zusmanovich M, Kester BS, Schwarzkopf R. Postoperative complications of total joint arthroplasty in obese patients stratified by BMI. J Arthroplasty 2018; 33 (03) 856-864
    CrossrefPubMedGoogle Scholar
  • 31 George J, Piuzzi NS, Ng M, Sodhi N, Khlopas AA, Mont MA. Association between body mass index and thirty-day complications after total knee arthroplasty. J Arthroplasty 2018; 33 (03) 865-871
    CrossrefPubMedGoogle Scholar
  • 32 Werner BC, Evans CL, Carothers JT, Browne JA. Primary total knee arthroplasty in super-obese patients: dramatically higher postoperative complication rates even compared to revision surgery. J Arthroplasty 2015; 30 (05) 849-853
    CrossrefPubMedGoogle Scholar
  • 33 Humphrey TJ, O'Brien TD, Melnic CM, Verrier KI, Bedair HS. MGB Arthroplasty Outcomes Writing Committee. Morbidly obese patients undergoing primary total joint arthroplasty may experience higher rates of venous thromboembolism when prescribed direct oral anticoagulants vs aspirin. J Arthroplasty 2022; 37 (06) 1189-1197
    CrossrefPubMedGoogle Scholar
  • 34 Meller MM, Goodman S, Gonzalez MH, Lau E. Does bariatric surgery normalize risks after total knee arthroplasty? Administrative medicare data. J Am Acad Orthop Surg Glob Res Rev 2019; 3 (12) 3
    PubMedGoogle Scholar
  • 35 Petersen PB, Kehlet H, Jørgensen CC. Lundbeck Foundation Centre for Fast-track Hip and Knee Replacement Collaborative Group. Safety of in-hospital only thromboprophylaxis after fast-track total hip and knee arthroplasty: a prospective follow-up study in 17,582 procedures. Thromb Haemost 2018; 118 (12) 2152-2161
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 Jørgensen CC, Jacobsen MK, Soeballe K. et al. Thromboprophylaxis only during hospitalisation in fast-track hip and knee arthroplasty, a prospective cohort study. BMJ Open 2013; 3 (12) e003965
    CrossrefPubMedGoogle Scholar
  • 37 Zuo J, Hu Y. Admission deep venous thrombosis of lower extremity after intertrochanteric fracture in the elderly: a retrospective cohort study. J Orthop Surg Res 2020; 15 (01) 549
    CrossrefPubMedGoogle Scholar
  • 38 Kim YJ, Choi DH, Ahn S, Sohn CH, Seo DW, Kim WY. Timing of pulmonary embolisms in femur fracture patients: incidence and outcomes. J Trauma Acute Care Surg 2016; 80 (06) 952-956
    CrossrefPubMedGoogle Scholar
  • 39 Tsantes AG, Papadopoulos DV, Trikoupis IG. et al. Rotational thromboelastometry findings are associated with symptomatic venous thromboembolic complications after hip fracture surgery. Clin Orthop Relat Res 2021; 479 (11) 2457-2467
    CrossrefPubMedGoogle Scholar
  • 40 Tsantes AG, Trikoupis IG, Papadopoulos DV. et al. Higher coagulation activity in hip fracture patients: a case-control study using rotational thromboelastometry. Int J Lab Hematol 2021; 43 (03) 477-484
    CrossrefPubMedGoogle Scholar
  • 41 Grant PJ, Jaffer AK. When should prophylactic anticoagulation begin after a hip fracture?. Cleve Clin J Med 2006; 73 (09) 785-786 , 788, 790–792
    CrossrefPubMedGoogle Scholar
  • 42 Anand S, Buch K. Post-discharge symptomatic thromboembolic events in hip fracture patients. Ann R Coll Surg Engl 2007; 89 (05) 517-520
    CrossrefPubMedGoogle Scholar
  • 43 Ho KM, Tan JA. Stratified meta-analysis of intermittent pneumatic compression of the lower limbs to prevent venous thromboembolism in hospitalized patients. Circulation 2013; 128 (09) 1003-1020
    CrossrefPubMedGoogle Scholar
  • 44 Khatri A, Davies AH, Shalhoub J. Mechanical prophylaxis for venous thromboembolism prevention in obese individuals. Phlebology 2021; 36 (10) 768-770
    CrossrefPubMedGoogle Scholar
  • 45 Shalhoub J, Lawton R, Hudson J. et al; GAPS trial investigators. Graduated compression stockings as adjuvant to pharmaco-thromboprophylaxis in elective surgical patients (GAPS study): randomised controlled trial. BMJ 2020; 369: m1309
    CrossrefPubMedGoogle Scholar
  • 46 Kakkos SK, Caprini JA, Geroulakos G. et al. Combined intermittent pneumatic leg compression and pharmacological prophylaxis for prevention of venous thromboembolism. Cochrane Database Syst Rev 2016; 9: CD005258
    PubMedGoogle Scholar
  • 47 Loh JLM, Chan S, Wong KL, de Mel S, Yap ES. Chemoprophylaxis in addition to mechanical prophylaxis after total knee arthroplasty surgery does not reduce the incidence of venous thromboembolism. Thromb J 2019; 17: 9
    CrossrefPubMedGoogle Scholar
  • 48 Crawford DA, Andrews RL, Morris MJ, Hurst JM, Lombardi Jr AV, Berend KR. Ambulatory portable pneumatic compression device as part of a multimodal aspirin-based approach in prevention of venous thromboembolism in outpatient total knee arthroplasty. Arthroplast Today 2020; 6 (03) 378-380
    CrossrefPubMedGoogle Scholar
  • 49 Nam JH, Kim DH, Yoo JH, Hwang JH, Chang JD. Does preoperative mechanical prophylaxis have additional effectiveness in preventing postoperative venous thromboembolism in elderly patients with hip fracture?-Retrospective case-control study. PLoS One 2017; 12 (11) e0187337
    CrossrefPubMedGoogle Scholar
  • 50 Falck-Ytter Y, Francis CW, Johanson NA. et al. Prevention of vte in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012; 141 (2, Suppl): e278S-e325S
    CrossrefPubMedGoogle Scholar
  • 51 Jacobs JJ, Mont MA, Bozic KJ. et al. American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Bone Joint Surg Am 2012; 94 (08) 746-747
    CrossrefPubMedGoogle Scholar
  • 52 Anderson DR, Morgano GP, Bennett C. et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. Blood Adv 2019; 3 (23) 3898-3944
    CrossrefPubMedGoogle Scholar
  • 53 Amarase C, Tanavalee A, Larbpaiboonpong V. et al; Asia-Pacific (AP) Region Venous Thromboembolism (VTE) Consensus Group. Asia-Pacific venous thromboembolism consensus in knee and hip arthroplasty and hip fracture surgery: Part 2. Mechanical venous thromboembolism prophylaxis. Knee Surg Relat Res 2021; 33 (01) 20
    CrossrefPubMedGoogle Scholar
  • 54 Morris RJ, Woodcock JP. Evidence-based compression: prevention of stasis and deep vein thrombosis. Ann Surg 2004; 239 (02) 162-171
    CrossrefPubMedGoogle Scholar
  • 55 Rabe E, Partsch H, Morrison N. et al. Risks and contraindications of medical compression treatment - a critical reappraisal. An international consensus statement. Phlebology 2020; 35 (07) 447-460
    CrossrefPubMedGoogle Scholar
  • 56 Morris RJ. Research quality in the study of mechanical methods of deep vein thrombosis prophylaxis. Phlebology 2020; 35 (05) 297-304
    CrossrefPubMedGoogle Scholar
  • 57 NICE Guideline [ng89]. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism. Accessed July 18, 2020 at: https://www.nice.org.uk/guidance/ng89/chapter/Recommendations#interventions-for-people-having-orthopaedic-surgery
    PubMedGoogle Scholar
  • 58 Tran VN, Varfolomeev I, Hill G. Prophylactic enoxaparin dosing in obese orthopedic patients: a literature search. Hosp Pharm 2020; 55 (06) 366-372
    CrossrefPubMedGoogle Scholar
  • 59 Abildgaard A, Madsen SA, Hvas AM. Dosage of anticoagulants in obesity: recommendations based on a systematic review. Semin Thromb Hemost 2020; 46 (08) 932-969
    Article in Thieme ConnectPubMedGoogle Scholar
  • 60 Patel JP, Roberts LN, Arya R. Anticoagulating obese patients in the modern era. Br J Haematol 2011; 155 (02) 137-149
    CrossrefPubMedGoogle Scholar
  • 61 McLeay SC, Morrish GA, Kirkpatrick CM, Green B. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin Pharmacokinet 2012; 51 (05) 319-330
    CrossrefPubMedGoogle Scholar
  • 62 Shelkrot M, Miraka J, Perez ME. Appropriate enoxaparin dose for venous thromboembolism prophylaxis in patients with extreme obesity. Hosp Pharm 2014; 49 (08) 740-747
    CrossrefPubMedGoogle Scholar
  • 63 Wang TF, Milligan PE, Wong CA, Deal EN, Thoelke MS, Gage BF. Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. Thromb Haemost 2014; 111 (01) 88-93
    Article in Thieme ConnectPubMedGoogle Scholar
  • 64 Shi S, Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metab 2011; 12 (07) 601-610
    CrossrefPubMedGoogle Scholar
  • 65 Nutescu EA, Spinler SA, Wittkowsky A, Dager WE. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 2009; 43 (06) 1064-1083
    CrossrefPubMedGoogle Scholar
  • 66 Frederiksen SG, Hedenbro JL, Norgren L. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients. Br J Surg 2003; 90 (05) 547-548
    CrossrefPubMedGoogle Scholar
  • 67 Lovenox (enoxaparin) prescribing information. Accessed June 17, 2021 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020164s110lbl.pdf
    PubMedGoogle Scholar
  • 68 Sebaaly J, Covert K. Enoxaparin dosing at extremes of weight: literature review and dosing recommendations. Ann Pharmacother 2018; 52 (09) 898-909
    CrossrefPubMedGoogle Scholar
  • 69 Wallace JL, Reaves AB, Tolley EA. et al. Comparison of initial warfarin response in obese patients versus non-obese patients. J Thromb Thrombolysis 2013; 36 (01) 96-101
    CrossrefPubMedGoogle Scholar
  • 70 Mueller JA, Patel T, Halawa A, Dumitrascu A, Dawson NL. Warfarin dosing and body mass index. Ann Pharmacother 2014; 48 (05) 584-588
    CrossrefPubMedGoogle Scholar
  • 71 McDougall CJ, Gray HS, Simpson PM, Whitehouse SL, Crawford RW, Donnelly WJ. Complications related to therapeutic anticoagulation in total hip arthroplasty. J Arthroplasty 2013; 28 (01) 187-192
    CrossrefPubMedGoogle Scholar
  • 72 Simpson PM, Brew CJ, Whitehouse SL, Crawford RW, Donnelly BJ. Complications of perioperative warfarin therapy in total knee arthroplasty. J Arthroplasty 2014; 29 (02) 320-324
    CrossrefPubMedGoogle Scholar
  • 73 Martin K, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost 2016; 14 (06) 1308-1313
    CrossrefPubMedGoogle Scholar
  • 74 Moll S, Crona DJ, Martin K. Direct oral anticoagulants in extremely obese patients: OK to use?. Res Pract Thromb Haemost 2018; 3 (02) 152-155
    CrossrefPubMedGoogle Scholar
  • 75 Eriksson BI, Dahl OE, Feuring M. et al. Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis. Thromb Res 2012; 130 (05) 818-820
    CrossrefPubMedGoogle Scholar
  • 76 Sebaaly J, Kelley D. Direct oral anticoagulants in obesity: an updated literature review. Ann Pharmacother 2020; 54 (11) 1144-1158
    CrossrefPubMedGoogle Scholar
  • 77 Martin KA, Beyer-Westendorf J, Davidson BL, Huisman MV, Sandset PM, Moll S. Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation. J Thromb Haemost 2021; 19 (08) 1874-1882
    CrossrefPubMedGoogle Scholar
  • 78 Afshari A, Ageno W, Ahmed A. et al; ESA VTE Guidelines Task Force. European guidelines on perioperative venous thromboembolism prophylaxis: executive summary. Eur J Anaesthesiol 2018; 35 (02) 77-83
    CrossrefPubMedGoogle Scholar
  • 79 Guidelines for vte prophylaxis for hip and knee arthroplasty-february 2018. Accessed July 18, 2020 at: https://www.aoa.org.au/about-aoa/subspecialties/arthroplasty
    PubMedGoogle Scholar
  • 80 Parvizi J, Ceylan HH, Kucukdurmaz F, Merli G, Tuncay I, Beverland D. Venous thromboembolism following hip and knee arthroplasty: the role of aspirin. J Bone Joint Surg Am 2017; 99 (11) 961-972
    CrossrefPubMedGoogle Scholar
  • 81 Rothwell PM, Cook NR, Gaziano JM. et al. Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet 2018; 392 (10145): 387-399
    CrossrefPubMedGoogle Scholar
  • 82 Bordeaux BC, Qayyum R, Yanek LR. et al. Effect of obesity on platelet reactivity and response to low-dose aspirin. Prev Cardiol 2010; 13 (02) 56-62
    CrossrefPubMedGoogle Scholar
  • 83 Arnett DK, Blumenthal RS, Albert MA. et al. 2019 acc/aha guideline on the primary prevention of cardiovascular disease: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. J Am Coll Cardiol 2019; 74 (10) e177-e232
    PubMedGoogle Scholar
  • 84 Marrannes S, Victor K, Arnout N, De Backer T, Victor J, Tampere T. Prevention of venous thromboembolism with aspirin following knee surgery: a systematic review and meta-analysis. EFORT Open Rev 2021; 6 (10) 892-904
    CrossrefPubMedGoogle Scholar
  • 85 Halbur CR, Gulbrandsen TR, West CR, Brown TS, Noiseux NO. Weight-based aspirin dosing may further reduce the incidence of venous thromboembolism following primary total joint arthroplasty. J Arthroplasty 2021; 36 (12) 3986.e1-3992.e1
    CrossrefPubMedGoogle Scholar
  • 86 Tang A, Sicat CS, Singh V, Rozell JC, Schwarzkopf R, Long WJ. Aspirin use for venous thromboembolism prevention is safe and effective in overweight and obese patients undergoing revision total hip and knee arthroplasty. J Arthroplasty 2021; 36 (7S): S337-S344
    CrossrefPubMedGoogle Scholar
  • 87 Horlocker TT, Vandermeuelen E, Kopp SL, Gogarten W, Leffert LR, Benzon HT. Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine evidence-based guidelines (fourth edition). Reg Anesth Pain Med 2018; 43 (03) 263-309
    CrossrefPubMedGoogle Scholar
  • 88 Schuetze K, Eickhoff A, Dehner C, Gebhard F, Richter PH. Impact of oral anticoagulation on proximal femur fractures treated within 24 h - a retrospective chart review. Injury 2019; 50 (11) 2040-2044
    CrossrefPubMedGoogle Scholar
  • 89 Tarrant SM, Catanach MJ, Sarrami M, Clapham M, Attia J, Balogh ZJ. Direct oral anticoagulants and timing of hip fracture surgery. J Clin Med 2020; 9 (07) 9
    CrossrefPubMedGoogle Scholar
  • 90 Lock JF, Ungeheuer L, Borst P. et al. Markedly increased risk of postoperative bleeding complications during perioperative bridging anticoagulation in general and visceral surgery. Perioper Med (Lond) 2020; 9 (01) 39
    CrossrefPubMedGoogle Scholar
  • 91 Douketis JD, Spyropoulos AC, Duncan J. et al. Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant. JAMA Intern Med 2019; 179 (11) 1469-1478
    CrossrefPubMedGoogle Scholar
  • 92 Maier CL, Sniecinski RM. Anticoagulation monitoring for perioperative physicians. Anesthesiology 2021; 135 (04) 738-748
    CrossrefPubMedGoogle Scholar
  • 93 Gu TM, Garcia DA, Sabath DE. Assessment of direct oral anticoagulant assay use in clinical practice. J Thromb Thrombolysis 2019; 47 (03) 403-408
    CrossrefPubMedGoogle Scholar
  • 94 Australian Arthroplasty Society of Australia. Guidlines for VTE prophylaxis for hip and knee arthroplasty. Accessed October 28, 2021 at: https://www.aoa.org.au/docs/default-source/ecm-files/guidelinesvteprophylaxis_050511_2.pdf?sfvrsn=2
    PubMedGoogle Scholar
  • 95 Scottish Intercollegiate Guidelines Network. Sign 122, prevention and management of venous thromboembolism, 2010. Accessed October 28, 2021 at: https://www.sign.ac.uk/our-guidelines/prevention-and-management-of-venous-thromboembolism/
    PubMedGoogle Scholar
  • 96 Wickham N, Gallus AS, Walters BN, Wilson A, Committee NVPGA. NHMRC VTE Prevention Guideline Adaptation Committee. Prevention of venous thromboembolism in patients admitted to Australian hospitals: summary of National Health and Medical Research Council clinical practice guideline. Intern Med J 2012; 42 (06) 698-708
    CrossrefPubMedGoogle Scholar
  • 97 Nicolaides AN, Fareed J, Kakkar AK. et al. Prevention and treatment of venous thromboembolism–international consensus statement. Int Angiol 2013; 32 (02) 111-260
    PubMedGoogle Scholar
  • 98 Liew NC, Alemany GV, Angchaisuksiri P. et al. Asian venous thromboembolism guidelines: updated recommendations for the prevention of venous thromboembolism. Int Angiol 2017; 36 (01) 1-20
    PubMedGoogle Scholar
  • 99 Liew NC, Chang YH, Choi G. et al; Asian Venous Thrombosis Forum. Asian venous thromboembolism guidelines: prevention of venous thromboembolism. Int Angiol 2012; 31 (06) 501-516
    PubMedGoogle Scholar
  • 100 Thiengwittayaporn S, Budhiparama N, Tanavalee C. et al; Asia-Pacific (AP) Region Venous Thromboembolism (VTE) Consensus Group. Asia-Pacific venous thromboembolism consensus in knee and hip arthroplasty and hip fracture surgery: part 3. Pharmacological venous thromboembolism prophylaxis. Knee Surg Relat Res 2021; 33 (01) 24
    CrossrefPubMedGoogle Scholar